EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lisata Therapeutics Inc. (LSTA) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Lisata Therapeutics Inc. $1.63, price $1.44, upside +13.6%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US1280583022

LT Lisata Therapeutics Inc. logo Thin data Sep 23, 2026

Lisata Therapeutics Inc.

LSTA · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $1.63 · Undervalued (+14%)
!Quality 25/100
!Weak Growth (revenue 3y −88.8 %/yr)
!negative free cash flow
!Trails peers (1/7)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
Watch Lisata Therapeutics Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$24.60 $0.9900 Fair Value $1.63 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.9900 – $24.60 · fair‑value band $1.07 – $2.03 · the $1.44 price screens below the $1.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Lisata Therapeutics in your weekly email

Every Wednesday you see whether Lisata Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.

Show more

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Stock analysis

Lisata Therapeutics Inc. (LSTA) currently trades at $1.44, while our model-based Fair Value estimate is $1.63, implying the stock looks roughly 12.0% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the evidence level at low.

Scenario range: $1.07 (bear) to $2.03 (bull), the price of $1.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Lisata Therapeutics Inc. reported revenue of $170K in FY2025 versus $0 in FY2021. Reported net income was −$16.6M in FY2025.

Key figures

Market cap $32.1M · EPS (TTM) $−1.87 · Return on equity −91.4% · Return on assets (EBIT) −64.5% · Operating margin −10,179% · Revenue (TTM) $170K · Revenue growth (YoY) −90.0% · Free cash flow −$16.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 72% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 14%, LSTA screens cheaper than that median.

Fair Value models

Bear $1.07 Fair Value $1.63 Bull $2.03
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.8200 $1.09 $1.63 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.8200 $1.09 $1.63 51

Open the full fair value analysis →

Notify me when LSTA reaches fair value

Put LSTA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 29 · Market factors (momentum, volatility) 15

Profitability 0
Margins and returns on capital today
Quality Growth 8
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 73
Disciplined investing over empire-building
Low Volatility 38
Calm price path (market factor)
Momentum 4
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 19
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−83.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−88.8%
Revenue growth 35 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.1% (1990) → −10,711.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch LSTA, get fair value alerts →

Compare Lisata Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside +14% · Top 25%
Profitability
Return on assets −50% · Bottom 25%
Growth and dividend
Revenue growth −90% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.16× · Pricier than median
PEG 118.40× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)51 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lisata Therapeutics Inc. · Fair Value
$1.63 +12%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lisata Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/LSTA

Frequently asked questions

Is Lisata Therapeutics Inc. (LSTA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $1.63 versus a price of $1.44, about +14% upside (undervalued).
What is the fair value of LSTA?
Our model-based fair value for Lisata Therapeutics Inc. is $1.63 (as of Sep 23, 2026), built from audited fundamentals. The current price: $1.44.
What is the quality score of LSTA?
Lisata Therapeutics Inc. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lisata Therapeutics Inc. (LSTA)?
Our model-based price target is the fair value of $1.63 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $1.07, optimistic scenario $2.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Lisata Therapeutics Inc. stock forecast for 2026?
Our models put fair value at $1.63, about +14% upside versus a price of $1.44 (undervalued). Cautious scenario $1.07, optimistic scenario $2.03. The calculation is refreshed regularly with new filings.
What is the revenue of Lisata Therapeutics Inc. (LSTA)?
Lisata Therapeutics Inc. reported trailing-twelve-month revenue of about $170K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Lisata Therapeutics Inc. (LSTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lisata Therapeutics Inc. it is $1.63 per share (as of Sep 23, 2026), against a price of $1.44. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lisata Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, LSTA trades below its calculated fair value: price $1.44, fair value $1.63, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LSTA?
No. The price is what the market pays today ($1.44); the fair value is what the company's own numbers justify ($1.63). For Lisata Therapeutics Inc. the two are $0.1950 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lisata Therapeutics Inc. worth?
The market values Lisata Therapeutics Inc. at about $32.1M (market capitalisation, as of Sep 23, 2026). Per share that is $1.44; our models calculate a fair value of $1.63 per share.
What do the bullish and bearish scenarios say about LSTA?
Our models span a range for Lisata Therapeutics Inc.: cautious scenario $1.07, base $1.63, optimistic $2.03 per share (as of Sep 23, 2026, price $1.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of LSTA?
The PEG ratio of Lisata Therapeutics Inc. is 118.40 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Lisata Therapeutics Inc. (LSTA)?
Balance-sheet figures for Lisata Therapeutics Inc. (as of Sep 23, 2026): return on equity −91.4%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is LSTA from its 52-week high?
Lisata Therapeutics Inc. trades at $1.44, about 72% below its 52-week high of $5.04 and 45% above the low of $0.9900 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $1.63 is for.
Which stocks are comparable to Lisata Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lisata Therapeutics Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price $1.44, calculated fair value $1.63 (+14%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LSTA calculated?
We run Lisata Therapeutics Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.63, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Lisata Therapeutics Inc. currently trades 14 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lisata Therapeutics Inc. (LSTA)?
The closing price on Sep 23, 2026 was $1.44. Our model-based fair value is $1.63, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lisata Therapeutics Inc. right now?
A fairly wide model range ($1.07 to $2.03) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Lisata Therapeutics Inc.

How large is the market capitalisation of Lisata Therapeutics Inc. (LSTA)?
The market capitalisation of Lisata Therapeutics Inc. is $32.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Lisata Therapeutics Inc. (LSTA)?
Earnings per share at Lisata Therapeutics Inc. are $−1.87. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lisata Therapeutics Inc. (LSTA)?
The return on equity (ROE) of Lisata Therapeutics Inc. is −91.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lisata Therapeutics Inc. (LSTA)?
On an EBIT basis the return on assets of Lisata Therapeutics Inc. is −64.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lisata Therapeutics Inc. (LSTA)?
The operating margin of Lisata Therapeutics Inc. is −10,179% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lisata Therapeutics Inc. (LSTA)?
Revenue at Lisata Therapeutics Inc. is growing −90.0% versus a year earlier (3y avg −88.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lisata Therapeutics Inc. (LSTA) generate?
The free cash flow of Lisata Therapeutics Inc. is −$16.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lisata Therapeutics Inc. (LSTA) hold?
Lisata Therapeutics Inc. holds more cash than debt, $16.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lisata Therapeutics Inc. in the live analysis

One click puts Lisata Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.